Alphabet's Isomorphic Labs: Turning Cancer Into a Chronic, But Livable Disease

Isomorphic Labs, a subsidiary of Alphabet Inc., is trying to use artificial intelligence to understand biology and transform the way new medicines are discovered and developed. Bloomberg's Tom Mackenzie spoke exclusively with the company's Chief AI Officer Max Jaderberg and its Head of Medicinal Drug Design Rebecca Paul about the technology behind their drug design engine and how it could reshape the future of healthcare, potentially turning cancer in a chronic, but livable disease. Watch the full episode: https://youtu.be/3IZagDdwIno Chapters: 00:00:00 - Isomorphic Labs building drug design engine 00:03:52 - AlphaFold breakthroughs 00:06:26 - How do we design these molecules? 00:08:22 - Data integrity in building AI tools for drug discovery 00:09:48 - Generalizability is key 00:12:08 - Why focus on immunology and oncology 00:16:15 - Novartis and Eli Lilly partnership 00:17:09 - Curing cancer 00:19:01 - Future of medicine -------- Like this video? Subscribe to Bloomberg Technology on YouTube: https://www.youtube.com/channel/UCrM7B7SL_g1edFOnmj-SDKg   Watch the latest full episodes of "Bloomberg Technology" with Caroline Hyde and Ed Ludlow here: https://www.youtube.com/playlist?list=PLfAX25ZLrPGTygCwn55voYZ_LYyKjxokJ   Get the latest in tech from Silicon Valley and around the world here: https://www.bloomberg.com/technology Connect with us on... X: https://twitter.com/technology Facebook: https://www.facebook.com/BloombergTechnology Instagram: https://www.instagram.com/bloombergbusiness/   Follow Ed Ludlow on X here: https://twitter.com/EdLudlow Follow Caroline Hyde on X here: https://twitter.com/CarolineHydeTV   Listen to the daily Bloomberg Technology podcast here: https://www.bloomberg.com/podcasts/series/bloomberg-technology   More from Bloomberg Business Connect with us on... X: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness Instagram: https://www.instagram.com/bloombergbusiness/ Linked